Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|August 12, 2019

Psychiatry Comic: Couchaholism

Author(s)Jon Carter

Laziness or disease? You decide.

Editor's note: This article was originally published on May 1, 2015 and has since been updated.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Cultural Competency and Community Engagement in Psychiatric Practice

Cultural Competency and Community Engagement in Psychiatric Practice

ByNaomi Dambreville, PhD

August 21st 2026

Why Cultural Context Matters in Psychiatric Assessment

Why Cultural Context Matters in Psychiatric Assessment

ByNaomi Dambreville, PhD

August 20th 2026

Asking About Identity: A Collaborative Approach to Patient Care

Asking About Identity: A Collaborative Approach to Patient Care

ByNaomi Dambreville, PhD

August 19th 2026

beach

The Night We Heard Ella Sing

ByRichard M. Berlin, MD

August 13th 2026

C Davids/peopleimages.com/Adobe Stock

Psyched Perspectives: Culturally Responsive Psychiatry, Insights From APA Fellow Diego Regalado, MD

ByFrank A. Clark, MD,Diego Regalado, MD

July 28th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG